Discontinued — last reported Q1 '18
Curtiss-Wright Allowance for Doubtful Accounts Receivable (Current) increased by 4.0% to $6.64M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.2%, from $5.44M to $6.64M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -3.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.35M | $6.53M | $5.32M | $4.81M | $5.36M | $4.54M | $4.69M | $5.22M | $4.62M | $4.23M | $4.03M | $4.53M | $5.48M | $5.06M | $4.20M | $5.44M | $6.23M | $6.86M | $6.39M | $6.64M |
| QoQ Change | — | -11.2% | -18.5% | -9.5% | +11.3% | -15.3% | +3.4% | +11.3% | -11.7% | -8.3% | -4.9% | +12.4% | +21.0% | -7.6% | -17.0% | +29.4% | +14.6% | +10.0% | -6.8% | +4.0% |
| YoY Change | — | — | — | — | -27.1% | -30.5% | -11.8% | +8.5% | -13.9% | -6.7% | -14.2% | -13.4% | +18.7% | +19.6% | +4.4% | +20.1% | +13.8% | +35.4% | +52.0% | +22.2% |